WilmerHale, Cooley Guide $100M Biotech IPOs
Cooley LLP-guided immuno-oncology firm Allogene Therapeutics on Friday unveiled a $100 million initial public offering in a bid to push ahead with its allogeneic T cell cancer therapies, while fellow biopharmaceutical...To view the full article, register now.
Already a subscriber? Click here to view full article